Αρχική World News EMA Recommends Extension of Indications for Sugemalimab World News EMA Recommends Extension of Indications for Sugemalimab Από Ogkologos - 28 Οκτωβρίου, 2025 497 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Tisotumab Vedotin 14 Φεβρουαρίου, 2025 Steps towards a smokefree society 31 Αυγούστου, 2022 Survivor Story: Erin 4 Ιουνίου, 2021 FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for Non-Small Cell Lung... 29 Οκτωβρίου, 2024 Φόρτωση περισσοτέρων HOT NEWS Aiming to support a robust regulatory ecosystem for driving cancer research... Cómo mi diagnóstico de cáncer a los 17 años cambió mi... Giving Myself the Most Time and Best Chance at Beating Cancer:... EMA Recommends Granting a Conditional Marketing Authorisation for Repotrectinib